OMERS ADMINISTRATION Corp Buys New Position in KORU Medical Systems, Inc. $KRMD

Key Points

• OMERS ADMINISTRATION Corp has acquired a new stake in KORU Medical Systems, purchasing 93,900 shares valued at approximately $239,000, representing about 0.20% of the company.
• KORU Medical Systems recently reported an earnings per share (EPS) of $0.01, exceeding analysts' expectations, alongside a revenue of $10.20 million for the quarter.
• Despite a negative P/E ratio of -45.56, KORU Medical Systems maintains an average analyst rating of "Buy" with a consensus target price of $4.63.

OMERS ADMINISTRATION Corp bought a new stake in KORU Medical Systems, Inc. (NASDAQ:KRMD - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 93,900 shares of the company's stock, valued at approximately $239,000. OMERS ADMINISTRATION Corp owned about 0.20% of KORU Medical Systems as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of KRMD. Raymond James Financial Inc. acquired a new stake in KORU Medical Systems in the 4th quarter valued at approximately $118,000. Northern Trust Corp increased its position in shares of KORU Medical Systems by 11.2% during the 4th quarter. Northern Trust Corp now owns 79,175 shares of the company's stock worth $305,000 after purchasing an additional 7,967 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of KORU Medical Systems during the 4th quarter worth approximately $143,000. Jane Street Group LLC increased its position in shares of KORU Medical Systems by 67.0% during the 4th quarter. Jane Street Group LLC now owns 68,923 shares of the company's stock worth $265,000 after purchasing an additional 27,664 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of KORU Medical Systems during the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 58.60% of the company's stock.

KORU Medical Systems Stock Performance

Shares of NASDAQ KRMD opened at $4.10 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.25 and a debt-to-equity ratio of 0.01. KORU Medical Systems, Inc. has a 12 month low of $1.86 and a 12 month high of $5.05. The stock has a 50 day moving average of $3.76 and a 200-day moving average of $3.20. The company has a market capitalization of $189.58 million, a P/E ratio of -45.56 and a beta of 0.57.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04. KORU Medical Systems had a negative return on equity of 26.77% and a negative net margin of 12.24%.The company had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.46 million. As a group, equities research analysts predict that KORU Medical Systems, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler lowered their price target on KORU Medical Systems from $4.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, KORU Medical Systems currently has an average rating of "Buy" and a consensus target price of $4.63.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.